[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Hattingen E, Blasel S, Nichtweiss M, Zanella FE, Weidauer S: MR imaging of midbrain pathologies. Clin Neuroradiol; 2010 Jun;20(2):81-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spectrum of pathologic processes affecting the midbrain features some differences to other brain areas.
  • Primary midbrain tumors are also infrequent and often show a benign clinical course.
  • Apart from multiple sclerosis other inflammatory autoimmune processes and some infectious agents predominantly affect the brainstem including the midbrain.
  • [MeSH-major] Brain Stem Hemorrhage, Traumatic / diagnosis. Brain Stem Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mesencephalon / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532857.001).
  • [ISSN] 1869-1447
  • [Journal-full-title] Clinical neuroradiology
  • [ISO-abbreviation] Clin Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 103
  •  go-up   go-down


2. Hughes SA, Achanta P, Ho AL, Duenas VJ, Quiñones-Hinojosa A: Biological horizons for targeting brain malignancy. Adv Exp Med Biol; 2010;671:93-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological horizons for targeting brain malignancy.
  • Though currently available clinical treatments and therapies have clearly extended the survival of patients with brain tumors, many of these advances are short lived, particularly with respect to high grade gliomas such as glioblastoma multiforme.
  • The missing link to an efficacious treatment of high grade gliomas is a more complete understanding of the basic molecular and cellular origin of brain tumors.
  • However, new discoveries of stem cell and developmental neurobiology have now borne the cancer stem cell hypothesis, drawing off of intriguing similarities between benign and malignant cells within the central nervous system.
  • Investigation of cancer stem cell hypothesis and brain tumor propagation is the current frontier of stem cell and cancer biology.
  • "Molecular neurosurgery", glioma treatments involving biologics using neural stem cells to target the cancer at the level of individual migratory cell, is a rapidly evolving field.
  • This coming progression of applied cancer stem cell research, coupled with current modalities, promises more comprehensive brain cancer interventions.
  • [MeSH-major] Brain Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Drug Delivery Systems. Genetic Therapy / methods. Glioma / pathology. Glioma / therapy. Neurons / physiology. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455498.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE: Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Mol Oncol; 2010 Dec;4(6):539-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring precancerous breast lesions.
  • A first step towards achieving this goal will be to define the molecular phenotypes of the various cell types and precursors - generated by the stem cell hierarchy - that are present in normal and benign conditions of the breast.
  • We review and present new data on the putative cell-progenitor marker cytokeratin 15 (CK15), and describe a novel marker, dihydropyriminidase-related protein 3 (DRP3) that in combination with CK15 and other well known proteins were used to define molecular phenotypes of normal human breast epithelial cells and their progenitors in resting acini, lactating alveoli, and large collecting ducts of the nipple.
  • [MeSH-major] Biomarkers / metabolism. Breast Neoplasms. Epithelial Cells / metabolism. Mammary Glands, Human. Phenotype. Proteomics / methods
  • [MeSH-minor] Databases, Protein. Electrophoresis, Gel, Two-Dimensional / methods. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-15 / metabolism. Keratin-19 / metabolism. Mass Spectrometry / methods. Muscle Proteins / metabolism. Protein Array Analysis / methods. Protein Isoforms / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • [Cites] Genes Dev. 2009 Nov 15;23 (22):2563-77 [19933147.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jun;133(6):852-4 [19492876.001]
  • [Cites] Int J Cancer. 1985 Sep 15;36(3):299-306 [2411673.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203 [16106024.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2009 Sep;45(8):442-50 [19533258.001]
  • [Cites] Pathology. 2009 Jan;41(1):36-9 [19089738.001]
  • [Cites] Mol Oncol. 2010 Oct;4(5):369-72 [20692213.001]
  • [Cites] Histopathology. 2008 Jan;52(1):11-9 [18171413.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(1):17-29 [19082706.001]
  • [Cites] J Pathol. 2009 Sep;219(1):131-40 [19562735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6 [20404174.001]
  • [Cites] Expert Rev Mol Diagn. 2010 May;10 (4):417-34 [20465497.001]
  • [Cites] Mol Diagn Ther. 2009 Dec 1;13(6):349-57 [19925032.001]
  • [Cites] J Pathol. 2006 Jul;209(3):307-16 [16604511.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):402-4 [8542598.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1337-44 [15042665.001]
  • [Cites] J Neurochem. 2005 Oct;95(2):466-74 [16135096.001]
  • [Cites] Mol Oncol. 2008 Dec;2(4):368-79 [19383358.001]
  • [Cites] J Surg Oncol. 1984 Jan;25(1):38-41 [6694391.001]
  • [Cites] Breast Cancer Res Treat. 1984;4(2):117-28 [6743838.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Mol Oncol. 2010 Aug;4(4):357-68 [20663721.001]
  • [Cites] Acta Oncol. 1988;27(1):1-19 [3284552.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] Climacteric. 2007 Oct;10 Suppl 2:47-53 [17882673.001]
  • [Cites] Nat Rev Drug Discov. 2010 Oct;9(10):767-74 [20811384.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] BMB Rep. 2010 Jun;43(6):383-8 [20587327.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):209-29 [20537966.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2815-23 [12684468.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):1023-34 [18024329.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Breast Cancer. 2002;9(3):254-6 [12185338.001]
  • [Cites] J Neurobiol. 1999 Oct;41(1):158-64 [10504203.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Mol Oncol. 2010 Oct;4(5):385-96 [20688584.001]
  • [Cites] Tissue Eng Part B Rev. 2010 Jun;16(3):351-9 [20092396.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):115-52 [19383333.001]
  • [Cites] Oncogene. 2010 Aug 12;29(32):4555-66 [20543870.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):778-83 [11064673.001]
  • [Cites] Gene. 1996 Nov 21;180(1-2):157-63 [8973361.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Mol Endocrinol. 2011 Feb;25(2):199-211 [20861225.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):496-510 [20934395.001]
  • [Cites] Breast J. 2005 Sep-Oct;11(5):326-32 [16174153.001]
  • [Cites] Pathology. 2009 Jan;41(1):18-27 [19089736.001]
  • [Cites] J Clin Pathol. 1996 Jan;49(1):48-52 [8666685.001]
  • [Cites] Breast Dis. 2008;29:57-67 [19029625.001]
  • [Cites] Mol Oncol. 2010 Feb;4(1):65-89 [20005186.001]
  • [Cites] Histopathology. 2010 Aug;57(2):171-92 [20500230.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):408-14 [8900376.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):713-7 [1385336.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12195-201 [9115293.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):24-32 [19383364.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):539-61 [21036680.001]
  • [Cites] Mol Oncol. 2010 Feb;4(1):19-37 [19913465.001]
  • [Cites] FEBS Lett. 2002 Dec 18;532(3):445-9 [12482610.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Maturitas. 2004 Sep 24;49(1):2-15 [15351091.001]
  • [Cites] Ann Oncol. 2008 May;19(5):1009-18 [18296422.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2317-27 [15160334.001]
  • [Cites] Hum Pathol. 2010 Jun;41(6):895-901 [20233620.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 26;309(3):558-66 [12963026.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17 ):1784-92 [16251534.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):593-5 [17164227.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Cell Stem Cell. 2010 Sep 3;7(3):403-17 [20804975.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2716-25 [15837986.001]
  • [Cites] Mol Cell Proteomics. 2010 Nov;9(11):2529-44 [20739354.001]
  • [Cites] Braz J Med Biol Res. 1996 Sep;29(9):1105-8 [9181052.001]
  • [Cites] Breast Cancer Res. 2002;4(6):224-30 [12473168.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):461-81 [20974554.001]
  • [Cites] Mod Pathol. 2010 May;23 Suppl 2:S1-7 [20436497.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Eur J Gynaecol Oncol. 2009;30(6):635-9 [20099493.001]
  • [Cites] Mol Neurobiol. 2003 Aug;28(1):51-64 [14514985.001]
  • [Cites] Clin Chem Lab Med. 2009;47(6):666-84 [19445650.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2893-917 [21351269.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jul;134(7):e48-72 [20586616.001]
  • [Cites] Nat Rev Cancer. 2010 Sep;10(9):605-17 [20720569.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Breast Cancer Res. 2003;5(5):263-8 [12927037.001]
  • [Cites] Electrophoresis. 1997 Dec;18(15):2832-41 [9504817.001]
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):190-203 [11169867.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res. 2003;5(5):254-7 [12927035.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Pathol Res Pract. 2007;203(11):765-9 [17931792.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Jan;2(1):19-27 [10887516.001]
  • [Cites] Adv Anat Pathol. 2005 Sep;12(5):256-64 [16210921.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):3978-87 [10962554.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):33-44 [19383365.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):511-28 [20851695.001]
  • [Cites] Breast Cancer Res. 2004;6(1):1-11 [14680479.001]
  • [Cites] Breast Cancer Res. 2005;7(3):131-42 [15987443.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Mod Pathol. 2010 May;23 Suppl 2:S8-13 [20436505.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Science. 2010 Jul 30;329(5991):568-71 [20671189.001]
  • [Cites] BMC Cancer. 2006 Apr 07;6:86 [16603054.001]
  • [Cites] Brain Res. 2006 Nov 13;1119(1):40-9 [16987501.001]
  • [Cites] Adv Cancer Res. 1997;71:241-319 [9111868.001]
  • [Cites] BMC Cancer. 2010 Aug 19;10 :444 [20723242.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):531-42 [11706048.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 21036680.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DPYSL3 protein, human; 0 / Keratin-15; 0 / Keratin-19; 0 / Muscle Proteins; 0 / Protein Isoforms
  •  go-up   go-down


Advertisement
4. Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res; 2009 Aug 15;15(16):5032-5039
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
  • PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves.
  • Significant morbidity can result from surgical treatment of these tumors.
  • Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2.
  • [MeSH-minor] Animals. Auditory Brain Stem Implants. Cochlear Implants. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Time Factors

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2002 Mar;20(3):475-82 [11836557.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):424-8 [17307835.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):332-9 [18285426.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1069-72 [17545869.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):978-86 [10215625.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):58-68 [18199958.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1063-71 [12066908.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Am J Otol. 1998 Sep;19(5):638-43 [9752973.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):577-81 [17726450.001]
  • [Cites] Stat Med. 1999 Aug 15;18(15):1905-42 [10532877.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 19671848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC009288
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS707923; NLM/ PMC4513640
  •  go-up   go-down






Advertisement